Drug Profile


Alternative Names: AD 32; N-Trifluoroacetyladriamycin-14-valerate; NSC 246131; Valstar; Valtaxin

Latest Information Update: 24 Jul 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anthra Pharmaceuticals
  • Developer Endo Pharmaceuticals Solutions
  • Class Anthracyclines; Antineoplastics; Cytostatics; Small molecules
  • Mechanism of Action DNA repair enzyme inhibitors; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Bladder cancer
  • Discontinued Endometrial cancer; Ovarian cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 24 Jul 2012 CTP alert for NCT01606345 - Endo Pharma is only the collaborator - not added
  • 14 Feb 2012 Endo Pharmaceuticals terminates a phase III trial in Bladder cancer in USA (NCT01310803)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top